SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%

SMS Pharmaceuticals Limited, a leading diversified and integrated pharmaceutical corporation specializing in Active Pharmaceutical Ingredients (APIs) and complex intermediates for a global clientele across more than 70 countries, has officially released its audited financial and operational results for the fourth quarter and full fiscal year ended March 31, 2026.

Fiscal Year 2026 Financial Highlights

SMS Pharmaceuticals delivered strong consolidated growth for the full fiscal year 2026, driven by operating leverage and structural cost advantages:

Profit After Tax (PAT): Full-year PAT experienced a remarkable 48% year-on-year surge, climbing to ₹102 crore (specifically ₹101.98 crore) from ₹69.14 crore in FY25. This net profit includes a substantial ₹14 crore (₹13.99 crore) share of profit contribution from the company's associate entity, VKT Pharma.

Revenue Operations: Total revenue from operations for FY26 reached ₹886.87 crore, marking a 13% increase over the ₹782.75 crore reported in the previous fiscal year, sustained by robust volumes in key API segments.

EBITDA & Margins: Full-year EBITDA rose 23% year-on-year to ₹171.28 crore. The corresponding EBITDA margin expanded by 155 basis points to reach 19%, up from 18% in FY25, highlighting the profitability gains of manufacturing efficiencies over transient market pricing benefits.

Gross Profit: Gross profit for the year escalated to ₹302.83 crore, yielding a stable annual gross profit margin of 34%.

Earnings Per Share (EPS): Annual EPS rose by 37% to ₹11.15 per share, up from ₹8.16 in FY25.

Shareholder Returns: In light of the strong fiscal performance, the Board of Directors has recommended a final dividend of ₹0.40 (40%) per share.

Fourth Quarter Review and Product Mix Shifts

For the final quarter of the fiscal year (Q4FY26), SMS Pharmaceuticals reported operational revenues of ₹237.95 crore, down slightly by 4% compared to ₹248.20 crore in Q4FY25. However, this nominal dip reflects an intentional, strategic optimization of the company's product portfolio.

Management actively redirected resource allocation away from lower-margin segments with shifting dynamics, notably the anti-diabetic sector, while scaling up focus on high-margin, high-scale categories like anti-inflammatory and Anti-Retro Viral (ARV) APIs.

Despite the minor revenue contraction in Q4, targeted cost optimization and backward integration allowed gross margins for the quarter to expand by 336 basis points year-on-year to 34% (generating ₹81.29 crore in gross profit). Q4FY26 EBITDA stood at ₹39.90 crore with a 17% margin, while quarterly PAT jumped 61% year-on-year to ₹32.71 crore.

Therapeutic Performance Analysis

The strategic pivot toward segments favoring backward integration and massive production capacities is visibly mirrored in the company's therapeutic area revenue streams for FY26:

Anti-Retro Viral (ARV): Emerged as the primary revenue generator, growing 55% to ₹251.80 crore, and now commands 28% of total revenue.

Anti-inflammatory: Showed strong upward traction, growing 20% to ₹177.05 crore, accounting for 20% of the company's total turnover.

Anti-diabetic: Successfully scaled down by 30% to ₹129.40 crore (dropping to 15% of total revenue from 24% last year) as part of the dynamic product mix optimization.

Niche Therapeutics: Substantial growth jumps were recorded in lesser-scaled segments, including Anti-epileptic APIs (up 85% to ₹54.15 crore) and Anti-anginal formulations (up 70% to ₹41.52 crore).

Other Segments: Anti-migraine brought in ₹93.81 crore (11% share); Anti-erectile dysfunction stood at ₹53.68 crore (6% share); Anti-ulcer generated ₹46.02 crore (5% share); and miscellaneous products contributed ₹39.44 crore.

Infrastructure Expansion and R&D Strengths

SMS Pharmaceuticals operates two state-of-the-art manufacturing plants located in Hyderabad and Vizag, boasting extensive capacities of 200 KL and 3,000 KL respectively. To bolster future growth, the company's ₹280 crore capital expenditure (Capex) program is currently moving on schedule and is tracking for total completion by FY27. These investments are slated to scale existing API capacities, introduce production pipelines for upcoming products, and significantly upgrade internal R&D capabilities.

On the regulatory and research front, the company completed 12 Drug Master File (DMF) and Certification of Suitability (CEP) filings during FY26. R&D momentum will be maintained with a target of 10 further regulatory submissions-spanning dossiers, DMF, and CEP filings-slated for FY27.

Forward Outlook for Fiscal Year 2027

Executive Director Mr. P. Vamsi Krishna expressed strong confidence in the structural cost benefits established by the business, stating that the company is ideally positioned to achieve over 15% top-line growth in FY27. Driven by deep-rooted backward integration, upcoming capacity completions, a strong associate contribution from VKT Pharma, and higher-margin product introductions, the company anticipates pushing its consolidated EBITDA margins into the 20% range for the next fiscal year.

Shares of SMS Pharmaceuticals Limited was last trading in BSE at Rs. 381.20 as compared to the previous close of Rs. 426.10. The total number of shares traded during the day was 66113 in over 2009 trades.

The stock hit an intraday high of Rs. 438.40 and intraday low of 374.60. The net turnover during the day was Rs. 26571207.00.

Source : Equity Bulls

Keywords

SMSPharmaceuticals INE812G01025 Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate